
MEDIA RELEASE

Burgdorf, 17th August 2011 – 7:00am – Richard Fritschi is leaving Ypsomed after five years to move to a start-up company in the dental industry. The primary shareholder as well as the board of directors of Ypsomed Holding AG regret his decision and thank him for his work and contribution. As of today and until further notice Dr. h.c. Willy Michel will assume the roles of CEO and chairman of the Ypsomed Group.

Further information is available from Ursula Rytz, Head of Marketing Communications at Ypsomed AG.

Tel. +41 34 424 41 43 or F. +41 34 424 41 11. This press release and additional information is available in electronic form at www.ypsomed.com

About the Ypsomed Group

The Ypsomed Group is a leading independent developer and manufacturer of injection systems for self-medication and a well-known diabetes specialist with more than 25 years' experience. The Ypsomed Group, which emerged in 2003 from the Disetronic Group, offers insulin pumps, injection systems and pen needles for diabetes, growth hormone and infertility treatments as well as for other therapeutic purposes. Ypsomed is an innovation and technology leader with an extensive patent portfolio and is the preferred partner of pharmaceutical and biotech companies in the self-medication sector. The Ypsomed Group has its headquarters in Burgdorf, Switzerland. It has several manufacturing sites in Switzerland as well as leading independent diabetes product sales companies throughout Europe. The Ypsomed Group employs approximately 1'150 employees.